“…Numerous studies have demonstrated that troglitazone (TRO), a synthetic PPARg ligand, causes growth inhibition, induces differentiation, and triggers apoptosis of various human malignant cells (Asou et al, 1999;Clay et al, 1999;Demetri et al, 1999;Sugimura et al, 1999;Hisatake et al, 2000;Rumi et al, 2001;Takashima et al, 2001;Begum et al, 2002;Yoshizawa et al, 2002). TRO inhibits proliferation of MCF-7 breast cancer cells by inducing cell cycle arrest and causing apoptosis (Yin et al, 2001).…”